<DOC>
	<DOCNO>NCT00908167</DOCNO>
	<brief_summary>This Phase I study determines tolerable combination sorafenib , give sequentially cytarabine clofarabine determines feasibility administer drug combination patient relapse refractory hematologic malignancy include acute myeloid leukemia ( AML ) , acute promyelocytic leukemia ( APL ) , acute lymphoblastic leukemia ( ALL ) , infantile leukemia ( either AML and/or ALL ) . AML prior myelodysplastic syndrome ( MDS ) , myelodysplastic/myeloproliferative neoplasm , biphenotypic leukemia .</brief_summary>
	<brief_title>Sorafenib Combination With Cytarabine Clofarabine Patients With Refractory Relapsed Hematologic Malignancies</brief_title>
	<detailed_description>Research perform patient age ≥ 0 month old &lt; 31 year old . In course 1 , sorafenib give orally ( PO ) day 1 7 . Pharmacokinetic study day 1 7 pharmacodynamic assessment day 8 perform . Inter-patient dose escalation de-escalation clofarabine sorafenib perform base tolerability toxicity . On day 8 12 , clofarabine cytarabine administer intravenously ( IV ) without concurrent twice daily sorafenib . Sorafenib give day 15 28 ( 14 day ) . Cytarabine clofarabine may give day 8 treat physician feel necessary consult primary investigator base participant 's clinical condition ( e.g . disease progression ) . Intrathecal ( IT ) methotrexate ( age-adjusted dos ) leucovorin rescue ( 24 30 hour IT therapy ) give day 8 . Participants central nervous system ( CNS ) disease receive IT therapy weekly cerebrospinal fluid ( CSF ) become free leukemia ( minimum 4 dos ) . Triple intrathecal therapy methotrexate , hydrocortisone cytarabine allow day 8 therapy . Response evaluation perform day 22 ( 15 day initiation cytarabine clofarabine ) first course . One course therapy 28 day unless disease progression see . Participants may receive subsequent course ( 5 course ) disease progression unacceptable toxicity . Sorafenib give day 1 7 15 28 subsequent course , cytarabine without clofarabine administer starting day 8 12 ( clofarabine remove course 2 ) .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients must diagnosis acute myeloid leukemia ( AML ) , acute promyelocytic leukemia ( APL ) , acute lymphoblastic leukemia ( ALL ) , infantile leukemia ( either AML ALL ) , AML prior myelodysplastic syndrome ( MDS ) , myelodysplastic/myeloproliferative neoplasm , biphenotypic leukemia . Patients treatmentrelated AML ( tAML ) eligible , provide meet eligibility criterion . Current disease status must one know curative therapy therapy proven prolong survival acceptable quality life . Patients must meet one follow criterion : 1 . First great relapse , 2 . Refractory 1 course induction reinduction chemotherapy , 3 . First great relapse allogeneic hematopoietic stem cell transplantation ( HSCT ) . Age : participant must &lt; 31 year age time study entry . St. Jude participant include follow : Participants currently therapy St. Jude , within 3 year complete therapy St. Jude must ≤ 24 year age . Other participant must ≤ 21 year age . Performance status : Karnofsky &gt; 50 % ≥ 16 year age ; Lansky &gt; 50 % child &lt; 16 year age . Organ Function Requirements : 1 . Hepatic : Serum direct bilirubin ≤2.0 mg/dl . Alanine transaminase ( ALT/SGPT ) ≤4 x ULN 2 . Cardiovascular : • Shortening fraction great equal 25 % echocardiogram 3 . Pulmonary : • Pulse oximetry ≥93 % room air 4 . Renal : • Creatinine clearance radioisotope GFR great equal 70 mL/min/1.73m2 serum creatinine base age 5 . Pancreas : Amylase lipase ≤ 2 × upper limit normal Participant legal guardian , opinion investigator , capable understanding investigational nature , potential risk benefit study , able provide valid inform consent . A sign informed consent must obtain prior study specific procedure . Participants relapse sorafenib therapy . Uncontrolled hypertension , define : Patients &lt; 18 year old : Diastolic Blood Pressure Within The Upper Limit Of Normal Defined : A diastolic blood pressure ( DBP ) &gt; 95th percentile age gender despite optimal medical management . Patients ≥ 18 year old Uncontrolled hypertension define systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 90 mmHg despite optimal medical management . . Use concomitant chemotherapy , investigational agent , radiation therapy , immunotherapy specify protocol . Use investigational agent within 30 day anticancer therapy within 2 week study entry exception hydroxyurea , low dose cytarabine intrathecal chemotherapy . Any severe concurrent disease , history serious organ dysfunction disease involve heart , kidney , liver , organ system may place participant undue risk undergo treatment . Participant systemic fungal , bacterial , viral infection control ( define exhibit ongoing signs/symptoms related infection without improvement ) , despite appropriate antibiotic treatment ) . Any significant concurrent disease , illness , psychiatric disorder would compromise participant safety compliance , interfere consent , study participation , followup , interpretation study result . Participants must receive concomitant medication know inhibit platelet function know selectively inhibit cyclooxygenase2 ( COX2 ) activity ( i.e. , antipyretic antiinflammatory medication except acetaminophen ) . There available information , yet , regard human fetal teratogenic toxicity . Pregnancy test negative result must obtain girl postmenarchal within 10 day start treatment . Women childbearing potential men must agree use adequate contraception ( barrier method birth control ) prior study entry duration study participation . Men woman use adequate birth control least three month last administration study treatment . Pregnant lactating . Known human immunodeficiency virus ( HIV ) infection . Thrombolic embolic event cerebrovascular accident include transient ischemic attack within past 6 month Cardiac disease : Congestive heart failure &gt; class II NYHA . Patients must unstable angina ( anginal symptom rest ) new onset angina ( begin within last 3 month ) myocardial infarction within past 6 month . Cardiac ventricular arrhythmia require antiarrhythmic therapy . Pulmonary hemorrhage/bleeding event &gt; CTCAE Grade 2 within 4 week first dose study drug . Any hemorrhage/bleeding event &gt; CTCAE Grade 3 within 4 week first dose study drug Serious nonhealing wound , ulcer , bone fracture . Evidence history bleed diathesis coagulopathy . Major surgery , open biopsy significant traumatic injury within 4 week first study drug . Concomitant use St. John 's Wort rifampin ( rifampicin ) Known suspect allergy agent give course trial . Any malabsorption problem . Have diagnosis another malignancy , unless participant diseasefree least 3 year follow completion curative intent therapy follow exception : Participants treat nonmelanoma skin cancer , situ , carcinoma , cervical intraepithelial neoplasia , regardless diseasefree duration , eligible study definitive treatment condition complete . Patients organconfined prostate cancer evidence recurrent progressive disease base prostatespecific antigen ( PSA ) value also eligible study hormonal therapy initiate radical prostatectomy perform . Participants opinion investigator may able comply safety monitoring requirement study . Inability unwillingness research participant legal guardian representative give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>31 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>sorafenib</keyword>
	<keyword>cytarabine</keyword>
	<keyword>clofarabine</keyword>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>acute promyelocytic leukemia</keyword>
	<keyword>acute lymphoblastic leukemia</keyword>
</DOC>